Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.52 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 6/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | HRH2 | P25021 | 4/20 | 0.41 |
| ▸ | HRH1 | P35367 | 4/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26814252 | 0.99 | KCNA3 (0.51) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL26814454 | 0.99 | KCNA3 (0.51) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL26813077 | 0.90 | KCNA3 (0.50) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL26813364 | 0.90 | KCNA3 (0.52) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL26814453 | 0.88 | KCNA3 (0.51) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL26814470 | 0.88 | KCNA3 (0.51) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL26814249 | 0.88 | KCNA3 (0.51) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL18609563 | 0.88 | KCNA3 (0.51) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL13612905 | 0.88 | KCNA3 (0.53) | KCNA3CTSKDRD2CCR5DRD3 | |
| SCHEMBL3460701 | 0.88 | KCNA3 (0.55) | KCNA3CTSKDRD2CCR5DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11833208-B2 | PLK1 selective degradation inducing compound | UPPTHERA, INC. (KR) | 2023-12-05 | — | — | US | disclosed |
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | UPPTHERA (KR) | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372498-A1 | PLK1 SELECTIVE DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | KCNA3 3663/4885CTSK 1058/4885DRD2 3885/4885 |
| US-11833208-B2 | PLK1 selective degradation inducing compound | PLK1, BUB1B, BUB1 | KCNA3 3663/4885CTSK 1058/4885DRD2 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.